Jaguar Health Provides Update On Special Stock Dividend; Nasdaq Sets October 16 Ex-Dividend Date

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives

Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027

SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today provided an update in connection with the Company's previously announced special stock dividend (the "Special Stock Dividend"), which is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, 2026, to announce that The Nasdaq Stock Market LLC ("Nasdaq") has indicated that the ex-dividend date for the Special Stock Dividend is October 16, 2026 (the "Ex-Dividend Date"). The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").

Nasdaq has advised the Company that its shares of common stock will trade with "due bills" representing an assignment of the right to receive the dividend from the record date of October 13, 2026 until the Ex-Dividend Date (this period of time representing the "Dividend Right Period").

Stockholders who sell their shares of common stock during the Dividend Right Period will be selling their right to the Special Stock Dividend. Due bills obligate a seller of shares of common stock to deliver the Special Stock Dividend payable on such shares of common stock to the buyer (the "Dividend Right"). The record date of October 13, 2026, will be used as the date for establishing the due bill tracking of the Dividend Right to the holder of shares of common stock.

Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares of common stock. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company's shares of common stock should consult their brokers before trading to be sure they understand the effect of Nasdaq's due bill procedures.